FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1637-1639 November 26, 1998 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Sigal, L. H. Related Article by Steere, A. C. Related Article by Sigal, L. H.

To the Editor: The studies by Steere et al.¹ and Sigal et al.² (July 23 issue) suggest that the vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A is well tolerated and efficacious and "provides an important new public health approach to the prevention of Lyme disease."¹ The role of this vaccine in public health efforts to prevent Lyme disease needs further consideration.

Many vaccines benefit public health by providing widespread immunity against potentially severe or fatal, and often untreatable, diseases. Vaccine-induced herd immunity against contagious diseases reduces the risk among unvaccinated persons. Lyme disease is a noncontagious, treatable, and . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.